Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$29.86 USD
+0.21 (0.71%)
Updated May 9, 2024 04:00 PM ET
After-Market: $29.85 -0.01 (-0.03%) 5:04 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 621 - 640 ( 717 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Potential Approval of Additional EXPAREL Manufacturing Facility Anticipated in Early April 2014
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Potential Approval of Additional EXPAREL Manufacturing Facility Anticipated in Early April 2014; Reiterate OUTPERFORM and $59 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
December 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
December 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
October Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $59 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
November and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q3 EXPAREL Sales Slightly Beat on Increased Traction in Orthopedics and iTAPs; Reiterate OUTPERFORM & $59 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
September Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $59 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
October and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
New Partnership with CrossLink Likely to Accelerate Utilization Among Orthopedics, in Our View; Reiterate OUTPERFORM and Moving to $59 12-Month PT
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $43 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
New Data Evaluating EXPAREL in Knee Surgery Demonstrates Medical and Economic Advantages Over Standard of Care; Reiterate OUTPERFORM and $43 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $43 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Aug. 12
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2 EXPAREL Sales Beat as Launch Begins to Pick Up Steam; Reiterate OUTPERFORM and $43 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August And Remaining 2013 Catalysts For Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Intercostal Nerve Block Trial Fails, But Nerve Block Indication Still Alive; Sell-off Overdone, In Our View; Reiterate OUTPERFORM and $43 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R